Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib plus azacitidine in MDS or MDS/MPN with myelofibrosis
CTR20210719Phase 2Terminated
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in Myelodysplastic syndrome (MDS), Myelodysplastic/Myeloproliferative Neoplasm (MDS/MPN), sponsored by Suzhou Zelgen Biopharmaceuticals. Started Apr 2021; status: terminated.
02
Drugs
jaktinib
03
Conditions
Myelodysplastic syndrome (MDS)Myelodysplastic/Myeloproliferative Neoplasm (MDS/MPN)
Beyond the preview
Go deeper on CTR20210719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210719.